In the hereditary disease hereditary angioedema (HAE), swellings occur in one or more parts of the body without a recognisable trigger. Especially if the upper respiratory tract is affected, a so-called HAE attack can be life-threatening. Active substances for on-demand medication are so far only available in the form of injections and infusions. In a phase 2 study led by the University Hospital Frankfurt and the Charité – Universitätsmedizin Berlin, it has now been shown for the first time that an orally administered active substance is effective. The therapy could replace the much more time-consuming and stressful injections.
For more information, please see the official press release and the abstract to the paper below.
Press Release Universitätsklinikum Frankfurt
Aygören-Pürsün E, Zanichelli A, Cohn DM, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Farkas H, Kiani-Alikhan S, Grivcheva-Panovska V, Bernstein JA, Li HH, Longhurst HJ, Audhya PK, Smith MD, Yea CM, Maetzel A, Lee DK, Feener EP, Gower R, Lumry WR, Banerji A, Riedl MA, Maurer M. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. Lancet. 2023 Feb 11;401(10375):458-469. doi: 10.1016/S0140-6736(22)02406-0. PMID: 36774155.
Read more news from ACARE
- April 12, 2024
A very warm welcome to our newest ACARE (and UCARE) Center in Madrid, Spain that was audited on March 22, 204: Hospital General Universitario Gregorio Marañón Allergy Department Head: Dr. [...]
- July 18, 2023
HAE TrackR allows you to download a comprehensive report of your treatments (preventative and on-demand) and attacks to be used as a tool for you and your physician. HAE TrackR [...]
- December 12, 2023
Join us for our first ACARE LevelUp webinar on 31st January 2024, 08:30 – 09:30 am CET. This webinar, with a focus on HAE, is designed to enable participants to: [...]